CM Life Sciences III Inc. just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:
424B3
1
ea153743-424b3_eqrxinc.htm
PROSPECTUS SUPPLEMENT
Filed
Pursuant to Rule 424(b)(3)
Registration No. 333-261786
Prospectus
Supplement No. 1
(to
Prospectus dated December 23, 2021)
Up
to 209,267,414 Shares of Common Stock
Up
to 19,733,333 Shares of Common Stock Issuable Upon Exercise of Warrants
Up
to 8,693,333 Warrants
This
prospectus supplement supplements the prospectus, dated Decem
ber 23, 2021 (the “Prospectus”), which forms a part of our registration
statement on Form S-1 (No. 333-261786). This prospectus supplement is being filed to update and supplement the information in the Prospectus
with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on January 10, 2022
(the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.
The
Prospectus and this prospectus supplement relate to the issuance by us of an aggregate of up to 19,733,333 shares of our common stock,
$0.0001 par value per share (“Common Stock”), which consists of (i) up to 8,693,333 shares of Common Stock that
are issuable upon the exercise of 8,693,333 warrants (the “Placement Warrants”) originally issued in a private
placement in connection with the initial public offering of CM Life Sciences III Inc. (“CMLS”) by the holders
thereof and (ii) up to 11,040,000 shares of Common Stock that are issuable upon the exercise of 11,040,000 warrants (the “Public
Warrants” and, together with the Placement Warrants, the “Warrants”) originally issued in the initial public
offering of CMLS by the holders thereof. We will receive the proceeds from any exercise of any Warrants for cash.
The
Prospectus and this prospectus supplement also relate to the offer and sale from time to time by the selling securityholders named in
the Prospectus (the “Selling Securityholders”) of (i) up to 209,267,414 shares of Common Stock (including up
to 8,693,333 shares of Common Stock that may be issued upon exercise
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever CM Life Sciences III Inc. makes a similar move, sign up!
